Literature DB >> 6931472

Clopenthixol and flupenthixol depot preparations in outpatient schizophrenics. III. Serum levels.

A Jrgensen, K F Overø.   

Abstract

Serum concentrations of clopenthixol and flupenthixol have been determined during a four weeks dosage interval in patients treated with intramuscular injections of clopenthixol decanoate or flupenthixol palmitate in Viscoleo. Maximal drug levels were attained by the end of the first week after injection of either preparation. A period of exponential decline was then recorded. The half-lives were estimated to 19 days for clopenthixol and 17 days for flupenthixol. These half-lives most likely refer to the rate of release from the oil depot and not to elimination of drug. The mean ratio between maximal and minimal drug levels was 2.5 for clopenthixol and 3.7 for flupenthixol. Systemic clearance was estimated to about 0.7 l/min and 0.5 l/min, respectively. Significant correlation was found between the administered doses and recorded serum levels, between doses and estimated areas under the serum concentration curves, and also between areas and drug levels. The data indicate more limited individual variability than that seen with other psychotropic drugs, given orally. The study clearly demonstrates, that significant serum levels of active drug is maintained throughout the dosage interval by intramuscular injection of clopenthixol decanoate or flupenthixol palmitate in Viscoleo every fourth week.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6931472     DOI: 10.1111/j.1600-0447.1980.tb07082.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  15 in total

1.  Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents.

Authors:  R Schindler
Journal:  Lipids       Date:  2001-05       Impact factor: 1.880

2.  Comparative study of the pharmacokinetics of zuclopenthixol decanoate and fluphenazine decanoate.

Authors:  A Viala; B Ba; A Durand; F Gouezo; N Hou; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

Review 3.  Antipsychotic drugs. Clinical pharmacokinetics of potential candidates for plasma concentration monitoring.

Authors:  A E Balant-Gorgia; L Balant
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

4.  Serum levels and clinical response in long-term pharmacotherapy with zuclopenthixol decanoate.

Authors:  B Szukalski; B Lipska; L Welbel; K Nurowska
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Zuclopenthixol decanoate in schizophrenia: serum levels and clinical state.

Authors:  A Jørgensen; T Aaes-Jørgensen; A Gravem; K F Amthor; S J Dencker; I Rosell; P C Baastrup; J Buckhave; L F Gram
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 6.  Clinical pharmacokinetics of the depot antipsychotics.

Authors:  M W Jann; L Ereshefsky; S R Saklad
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

7.  Blood and plasma kinetics of cis(Z)-clopenthixol and fluphenazine in psychiatric patients after intramuscular injection of their decanoic esters.

Authors:  A Viala; N Hou; B Ba; A Durand; H Dufour; N D'Agostino; C Berda; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

8.  Variation in oro-facial tardive dyskinesia during depot antipsychotic drug treatment.

Authors:  T R Barnes; D H Wiles
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Serum concentrations of the isomers of clopenthixol and a metabolite in patients given cis(Z)-clopenthixol decanoate in viscoleo.

Authors:  T Aaes-Jørgensen; L Kirk; E Petersen; P Danneskiold-Samsøe; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

10.  Steady-state serum concentrations after cis (Z)-flupentixol decanoate in viscoleo.

Authors:  J K Saikia; A Jørgensen
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.